Martina M. Fischer-Uttenreuther

Birkendorfer Str 65
Biberach An Der Riss, BW 88397, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Utility of real-world evidence in biosimilar development.

Utility of real-world evidence in biosimilar development.

Journal: Journal of biopharmaceutical statistics

Published: April 17, 2024

Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.

Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.

Journal: Pediatric blood & cancer

Published: March 31, 2021

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: July 11, 2018

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 20, 2018

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Journal: British journal of cancer

Published: January 20, 2017

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: June 15, 2016

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Journal: PLoS medicine

Published: April 12, 2016

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 08, 2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: August 27, 2015

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

Journal: Cancer chemotherapy and pharmacology

Published: June 22, 2015

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 05, 2015

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

Journal: SpringerPlus

Published: February 12, 2015

Showing 1-12 of 24

Last Updated: 09/26/2026